About

We are a venture capital-backed, clinical-stage company pioneering the development of human-equivalent, bioactive compounds as new medicines, initially focused on oligosaccharides found in human milk. We believe human-identical oligosaccharides have the potential to be differentiated and transformative new medicines due to their safety and multiple beneficial mechanisms of action enabling them to be a solution for patients underserved by conventional pharmaceutical approaches – who collectively represent the majority of people suffering from chronic inflammatory diseases and disorders of the gut-brain axis.